Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone

NCT00240006 ·Status: COMPLETED ·Phase: PHASE4

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

NCT02086188 ·Status: COMPLETED ·Phase: PHASE4

MS PATHS Normative Sub-Study

NCT02996084 ·Status: COMPLETED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

NCT07085507 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®

NCT05575843 ·Status: COMPLETED ·Phase: NA

Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease

NCT04540861 ·Status: NO_LONGER_AVAILABLE

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

NCT00395317 ·Status: COMPLETED ·Phase: PHASE2

Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

NCT03926637 ·Status: TERMINATED

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

NCT07207148 ·Status: RECRUITING

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

NCT01235221 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

NCT06868628 ·Status: RECRUITING ·Phase: PHASE2

Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

NCT00548769 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490 ·Status: RECRUITING ·Phase: PHASE2

Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03822858 ·Status: AVAILABLE

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

NCT02045732 ·Status: TERMINATED ·Phase: PHASE1

Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis

NCT02440516 ·Status: COMPLETED ·Phase: NA

The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections

NCT00988988 ·Status: WITHDRAWN ·Phase: PHASE4

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

NCT01738347 ·Status: COMPLETED ·Phase: PHASE1

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

NCT00097331 ·Status: COMPLETED ·Phase: PHASE2

The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis

NCT06599307 ·Status: RECRUITING ·Phase: PHASE2

A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.

NCT01466322 ·Status: COMPLETED ·Phase: PHASE1

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

NCT00930553 ·Status: COMPLETED ·Phase: PHASE3

Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System

NCT04599023 ·Status: TERMINATED

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237 ·Status: RECRUITING ·Phase: PHASE2

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

NCT01167426 ·Status: COMPLETED ·Phase: PHASE3